Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00003055 · ClinicalTrials.gov registry record · Phase 2

Cisplatin and Irinotecan in Treating Patients With Locally Advanced or Metastatic Esophageal or Gastric Cancer

A Phase 2 study, sponsored by Memorial Sloan Kettering Cancer Center.

Completed
Registry status
Phase 2
Development phase

NCT00003055: Completed Phase 2 study, sponsored by Memorial Sloan Kettering Cancer Center.

NCT00003055 is a Phase 2 study that has completed, run by Memorial Sloan Kettering Cancer Center. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT00003055, a Phase 2 study, has completed, sponsored by Memorial Sloan Kettering Cancer Center.

COMPLETED
Registry status
Phase 2
Development phase

Study Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy in treating patients with locally advanced or metastatic esophageal or gastric cancer.

Interventions

  • DRUG cisplatin
  • DRUG irinotecan hydrochloride

Trial Details

FieldValue
Start Date 1997-06
Est. Completion 2001-04
Phase Phase 2
Memorial Sloan Kettering Cancer Center

1,884 total trials

What the finished NCT00003055 record still lists

NCT00003055 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.

The record links to 0 conditions, and to 2 interventions - of which cisplatin is the first listed.

NCT00003055 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00003055 about?

NCT00003055 is a clinical study titled "Cisplatin and Irinotecan in Treating Patients With Locally Advanced or Metastatic Esophageal or Gastric Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy in treating patients with locally advanced o...

What is the current status of trial NCT00003055?

This trial is currently completed. It is a Phase 2 study. The study started on 1997-06. Estimated completion is 2001-04.

What interventions are being tested in trial NCT00003055?

The interventions under investigation include: cisplatin (DRUG), irinotecan hydrochloride (DRUG).

Who is sponsoring clinical trial NCT00003055?

This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00003055, the US trial registry maintained by the National Library of Medicine. NCT00003055 (unsized enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.